DharmaFECT Cell Type Guide

Choose DharmaFECT 1, 2, 3, or 4 for optimal siRNA transfection

The table below lists transfection recommendations to help you select the appropriate DharmaFECT formulation for your research. You can also download a PDF version of the DharmaFECT Cell Type Guide.

Cell line Cell type Recommended DharmaFECT formulation DharmaFECT volume/well (μl) in 96 well plate Plating density in 96 well plate (cells per well) Other successful formulations
Human
786-0 Kidney adenocarcinoma 1 0.4 5 × 103 2
A549 Lung carcinoma

1

0.2

1 × 104

2, 3, 4

BxPC3

Pancreas adenocarcinoma

2

0.2

5 × 103

1, 3, 4

DLD-1

Colorectal adenocarcinoma

2

0.4

5 × 103

1,3

DU 145

Prostate carcinoma

1

0.2

1 × 104

2, 3, 4

NCI-h2299

Lung carcinoma

2

0.2

1 × 104

4

HCT-116

Colorectal carcinoma

2

0.1

5 × 103

4

HEK293

Kidney transformed embryonic cells

1

0.2

1 × 104

2, 4

HeLa

Cervical epithelial adenocarcinoma

1

0.2

5 × 103

2, 3, 4

HeLa S3

Cervical epithelial adenocarcinoma

4

0.4

5 × 103

1, 2, 3

Hep G2

Hepatocellular carcinoma

4

0.4

1 × 104

1, 2

hMSC

Mesenchymal stem cells

1

0.4

5 × 103

2, 3, 4

HT-29

Colorectal carcinoma

1

0.2

5 × 103

2, 3, 4

HT1080

Fibrosarcoma

4

0.2

5 × 103

1, 2, 3

Huh-7

Hepatocarcinoma

4

0.05

5 × 103

1, 2

HUVEC

Umbilical vein endothelial cells

4

0.2

2 × 104

1, 2

LNCaP

Prostate carcinoma

3

0.2

1 × 104

1

MCF-10a

Breast adenocarcinoma

1

0.2

1 × 104

2

MCF-7

Breast adenocarcinoma

1

0.2

1 × 104

2, 4

MDA-MB-453

Breast adenocarcinoma

2

0.2

1 × 104

1, 3, 4

MDA-MB-231

Breast adenocarcinoma

4

0.1

5 × 103

1

OVCAR-3

Ovarian adenocarcinoma

1

0.1

5 × 103

2, 3, 4

PC-3

Prostate carcinoma

2

0.2

1 × 104

3

SK-BR3

Breast adenocarcinoma

2

0.2

1 × 104

1, 3, 4

SK-OV-3

Ovarian adenocarcinoma

3

0.4

1 × 104

1, 2, 4

u87MG

Brain glioblastoma

1

0.1

5 × 103

2, 3, 4
Cell line Cell type Recommended DharmaFECT formulation DharmaFECT volume/well (μl) in 96 well plate Plating density in 96 well plate (cells per well) Other successful formulations
Rodent

A7r5

Rat aortic smooth muscle

2

0.1

5 × 103

1

C2C12

Mouse myoblasts

1

0.2

5 × 103

2, 3, 4

CHO K1

Chinese hamster ovary cells

4

0.8

1 × 104

1, 2

ES-D3

Mouse embryonic stem cells

1

0.2

2 × 103

2

ES-E14TG2a

Mouse embryonic stem cells

1

0.2

2 × 103

2

H9c2

Rat myoblasts

1

0.2

1 × 104

2, 3, 4

J774A.1

Mouse macrophages

4

0.2

1 × 104

-

NIH/3T3

Mouse embryonic fibroblasts

1

0.2

1 × 104

3

NRK-49F

Rat kidney fibroblasts

2

0.2

1 × 104

1, 4

Rat2

Rat fibroblasts

1

0.2

2 × 104

2

3T3-L1

Mouse embryonic fibroblasts

1

0.2

5 × 103

3
Cell line Cell type Recommended DharmaFECT formulation DharmaFECT volume/well (μl) in 96 well plate Plating density in 96 well plate (cells per well) Other successful formulations
Non-human primate

COS-7

African green monkey kidney

2

0.4

5 × 103

1, 3, 4

All experimental conditions resulted in cell viability and positive control gene silencing of 80% or better All experiments were done in 96-well plates with Non-targeting control siRNA and PPIB (Cyclophilin B) or GAPD Control pools at 25 nM; Alamar Blue (viability) and knockdown measured at 24 hr Data normalized to untransfected for viability and both untransfected and Non-targeting control for knockdown Transfection conditions should always be re-evaluated in the context of a new plate format or assay-specific requirements for cell density